Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Detalles Bibliográficos
Publicado en:Lancet Oncology Vol. 27; no. 8; pp. 941 - 959
Autores principales: Turner, Nicholas C, Mayer, Erica L, Park, Yeon Hee, Janni, Wolfgang, Ma, Cynthia, Cristofanilli, Massimo, Bianchini, Giampaolo, Kalinsky, Kevin, Iwata, Hiroji, Chia, Stephen, Brufsky, Adam M, Fasching, Peter A, Nowecki, Zbigniew, Pascual, Javier, Karadurmus, Nuri, Gal-Yam, Einav, Chung, Wei-Pang, Im, Seock-Ah, Zambelli, Alberto, Dalenc, Florence
Formato: Journal Article
Publicado: Elsevier B.V. Aug2026
Acceso en línea:Ver este registro en EBSCOhost